Showing 5991-6000 of 7138 results for "".
- Paratek To Complete Omadacycline Phase 3 Skin Trial Earlier Than Expectedhttps://practicaldermatology.com/news/paratek-completes-enrollment-for-omadacycline-phase-3-skin-trial-earlier-than-expected/2458767/Paratek Pharmaceuticals, Inc. may report top-line data from its ongoing pivotal Phase 3 clinical trial evaluating omadacycline for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSS
- Immune and BioNanoSim Enter Agreement to Develop Novel Topical Nano-Capsule Formulation of Cyclosporinehttps://practicaldermatology.com/news/immune-and-bionanosim-enter-agreement-to-develop-novel-topical-nano-capsule-forumlation-of-cyclosporine/2458768/Immune Pharmaceuticals Inc. entered into an exclusive worldwide licensing and development agreement with BioNanoSim Ltd. for a novel topical nano-capsule formulation of cyclosporine, also known as cyclosporine-A or CsA. Monica Luchi, M.D., Chief Medical Officer of Immune, commented: "
- Brickell Biotech Achieves Positive Phase 2b Results for BBI-4000 for Hyperhidrosishttps://practicaldermatology.com/news/brickell-biotech-achieves-postive-phase-2b-results-for-bbi-4000-for-hyperhidrosis/2458772/Brickell Biotech, Inc. shared the results of its Phase 2b study of BBI-4000 (sofpironium bromide) for the topical treatment of primary axillary hyperhidrosis, or excessive underarm sweating. The multicenter, randomized, double blind, vehicle-controlled Phase 2b study was designed to evaluate the
- FDA Grants ReCell Expedited Access Pathway Designation to Treat Burnshttps://practicaldermatology.com/news/fda-grants-recell-expedited-access-pathway-designation-to-treat-burns/2458782/The FDA has ruled that the ReCell® Autologous Cell Harvesting Device from Avita Medical Ltd. is eligible for earlier regulatory approval for burns treatment. The ruling came under new FDA guidelines called the Expedited Access Pathway (EAP), which are aimed at helping patients get mor
- AADA Supports New Bill to Protect Senior Access to Dermatologic Carehttps://practicaldermatology.com/news/aada-supports-new-bill-to-protect-senior-access-to-dermatologic-care/2458781/The American Academy of Dermatology Association (AADA) supports the Medicare Advantage Bill of Rights Act, introduced by Sen. Sherrod Brown (D-Oh.) and Rep. Rosa DeLauro (D-Conn.). If passed, the legislation would ensure that patients will have adequate physician networks in their Medicare Advant
- Valeant Enters Fulfillment Agreements With Walgreenshttps://practicaldermatology.com/news/valeant-enters-fulfillment-agreements-with-walgreens/2458783/Valeant Pharmaceuticals International, Inc. entered into new fulfillment agreements with Walgreens and indicated that it intends to extend this distribution model to additional participating independent retail pharmacies. In conjunction with the fulfillment agreement, Valeant says it will reduce
- Aclaris Therapeutics, Inc. Appoints Brett Fair as Senior Vice President of Commercial Operationshttps://practicaldermatology.com/news/aclaris-therapeutics-inc-appoints-brett-fair-as-senior-vice-president-of-commercial-operations/2458784/Aclaris Therapeutics, Inc. has appointed Brett Fair as Senior Vice President of Commercial Operations. Mr. Fair brings more than 18 years of pharmaceutical commercialization and business
- Safe, Inexpensive Chemical Found to Reverse Symptoms of Progeria in Human Cellshttps://practicaldermatology.com/news/safe-inexpensive-chemical-found-to-reverse-symptoms-of-progeria-in-human-cells/2458787/New work from the University of Maryland suggests that a common, inexpensive and safe chemical called methylene blue could be used to treat progeria—and possibly the symptoms of normal aging as well. A new study shows for the first time that small doses of methylene blue can almost complete
- Valeant Offers Comment on Fake Twitter Accounthttps://practicaldermatology.com/news/valeant-offers-comment-on-fake-twitter-account/2458786/Valeant issued the following statement about a fake Twitter account created to impersonate Mike Pearson: We are aware that someone impersonating Mike Pearson has created an account on Twitter, and we have contacted Twitter to report the unauthorized use. Mike Pearson does not
- AAD Issues Statement on Skin Cancer Screeninghttps://practicaldermatology.com/news/aad-issue-statement-on-skin-cancer-screening/2458789/Mark G. Lebwohl, MD, FAAD, President, American Academy of Dermatology issued the following statement on skin cancer screenings: “The American Academy of Dermatology believes that early detection is vital in the fight against skin cancer, the most common cancer in the United States.